Related Experiment Video

Updated: Sep 10, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.5K

Ruxolitinib alleviated muscle atrophy in cancer cachexia by inhibiting IL-6/JAK/STAT3 signaling pathway in mice

Cong Li1, Xiaofan Gu1, Zixia Zhu1

  • 1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, PR China.

The Journal of Pharmacy and Pharmacology
|August 20, 2025
PubMed
Abstract

Insights

Ruxolitinib (Rux) effectively combats cancer cachexia by preventing muscle atrophy and body weight loss in preclinical models. This Janus tyrosine Kinase inhibitor works by inhibiting STAT3 signaling, offering a potential new treatment for cancer-related muscle wasting.

Area of Science:

  • Oncology
  • Pharmacology
  • Muscle Biology

Background:

  • Cancer cachexia is a complex metabolic syndrome characterized by involuntary weight loss and muscle wasting.
  • Skeletal muscle atrophy contributes significantly to morbidity and mortality in cancer patients.
  • Ruxolitinib (Rux), a Janus tyrosine Kinase (JAK) inhibitor, has shown anti-inflammatory effects and efficacy in mitigating muscle atrophy.

Purpose of the Study:

  • To investigate the efficacy of Ruxolitinib in treating cancer cachexia.
  • To elucidate the underlying mechanisms by which Ruxolitinib may exert its effects on cancer cachexia.

Main Methods:

  • In vitro studies using C2C12 myotubes exposed to C26 or LLC conditioned media to assess Ruxolitinib's impact on myotube atrophy.
  • In vivo studies utilizing a C26 tumor-bearing mouse model to evaluate Ruxolitinib's effects on cachexia symptoms.
  • Western blot analysis to explore the molecular mechanisms of Ruxolitinib action.

Main Results:

  • Ruxolitinib significantly reduced myotube atrophy in vitro.
  • Ruxolitinib suppressed interleukin-6 secretion by inhibiting STAT3 activation in tumor cells and macrophages.
  • In tumor-bearing mice, Ruxolitinib administration prevented body weight loss and muscle wasting without impacting tumor growth, leading to a 6.7% increase in body weight compared to controls.
  • Ruxolitinib treatment improved gastrocnemius muscle cross-sectional area and grip strength.

Conclusions:

  • Ruxolitinib ameliorates cancer cachexia-induced muscle atrophy through the inhibition of STAT3/Atrogin-1 signaling.
  • Ruxolitinib demonstrates potential as a therapeutic agent for managing cancer cachexia.
Keywords:
IL-6/JAK/STAT3Ruxcancer cachexiamacrophagesmuscle atrophysystemic inflammatory response

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K